Insilico Medicine Showcases AI-Driven Inhaled Rentosertib Program at Major Respiratory Meeting

According to a recent LinkedIn post from Insilico Medicine, the company plans to participate in the American Thoracic Society International Conference 2026 in Orlando with four presentations on its AI-driven inhaled Rentosertib (ISM018_055) program for pulmonary fibrosis. The post also indicates that Insilico Medicine has been selected as the 2026 Respiratory Innovation Summit Featured Success Story, focusing on its work in inhaled rentosertib.

The company’s LinkedIn post highlights themes spanning AI-discovered targets, inhaled therapeutic delivery, and early-stage clinical development, including safety, tolerability, and Phase I study design considerations. For investors, this emphasis suggests continued advancement of Insilico’s respiratory pipeline and reinforces its positioning as an early mover in applying generative AI to drug discovery in pulmonary indications.

The post suggests that Insilico intends to showcase AI-generated TNIK inhibition for pulmonary fibrosis and targeted lung exposure via inhaled delivery approaches, which could differentiate its technology and asset profile in a competitive fibrosis landscape. If the program progresses successfully through clinical stages, it may enhance the company’s asset value and partnership potential, particularly with larger pharma seeking AI-enabled respiratory therapies.

By framing inhaled rentosertib as part of a broader vision for AI-driven respiratory drug discovery, the LinkedIn content underscores Insilico’s strategic focus on integrating computational platforms with translational and clinical work. This visibility at ATS and the Respiratory Innovation Summit may support the company’s reputation, attract potential collaborators, and contribute indirectly to fundraising or strategic transaction opportunities, though clinical risk and regulatory uncertainty remain significant.